Myriad Genetics
myriad.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Myriad Genetics develops molecular diagnostic tests across oncology, women's health and mental health. Its hereditary cancer panels are among the most widely ordered genetic tests. The company also offers prenatal screening and pharmacogenomic products.
News
Beyond Eligibility: The Real Impact of the 2026 NCCN Genetic Testing Updates
A Paradigm Shift in Hereditary Cancer Testing Every addition to a clinical testing guideline represents more than a technical change. It may represent a patient whose hereditary cancer risk was previously unrecognized, a family that never received cascade
Read more
Report
Piper Sandler Keeps Their Buy Rating on Myriad Genetics (MYGN)
Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.
Read more
Report
How Myriad Genetics rebuilt its AI document-processing tool with AWS
Myriad Genetics partners with AWS to enhance Image Genius, speeding up document processing, and improving insurance workflows for diagnostics.
Read more
Report
Myriad Genetics Launches New Four-in-One Prenatal Genetic Screen
Myriad Genetics launches FirstGene Multiple Prenatal Screen, enabling four prenatal genetic tests from a blood draw as early as eight weeks.
Read more
Report
Pro access
Upgrade to see all 29 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.